Physician profile
Imran Aslam
NPI 1992199244
$280,486.54
in general payments reported to CMS, 2019-2025
32 companies · $147K in 2025
The $147K reported for 2025 was more than what 98% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $195 · 2020: $170 · 2021: $875 · 2022: $8,190 · 2023: $46K · 2024: $78K · 2025: $147K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $212K · Consulting Fee: $31K · Food and Beverage: $19K · Travel and Lodging: $9,038 · Education: $288.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $212,331.02 |
| Consulting Fee | $30,611.35 |
| Food and Beverage | $18,787.34 |
| Travel and Lodging | $9,038.49 |
| Education | $287.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $92,416.03 | 2020-2025 | Aklief, Epsolay, Nemluvio |
| Leo Pharma INC. | $76,582.59 | 2021-2025 | Adbry, Anzupgo |
| Janssen Biotech, INC. | $39,307.97 | 2021-2025 | Tremfya, Simponi, Simponi Aria |
| Incyte Corporation | $34,538.97 | 2021-2025 | Opzelura, Opzelura |
| E.R. Squibb & Sons, L.L.C. | $11,042.58 | 2022-2025 | Sotyktu |
| Genzyme Corporation | $7,535.26 | 2022-2025 | |
| Pfizer INC. | $5,814.98 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $4,112.05 | 2020-2025 | Dupixent, Libtayo |
| Abbvie INC. | $1,966.97 | 2019-2025 | Skyrizi, Rinvoq, Botox |
| Arcutis Biotherapeutics, INC. | $1,593.50 | 2023-2025 | Zoryve |
| Lilly USA, LLC | $689.55 | 2020-2025 | Taltz, Olumiant, Ebglyss |
| Journey Medical Corporation | $557.98 | 2022-2023 | |
| Dermavant Sciences, INC. | $552.75 | 2022-2024 | Vtama |
| Ucb, INC. | $510.65 | 2021-2025 | Bimzelx, Cimzia |
| Botanix Sb INC | $457.15 | 2025 | Sofdra |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $449.45 | 2021-2025 | |
| Amgen INC. | $352.64 | 2021-2025 | Otezla, Otezla, Enbrel |
| Sun Pharmaceutical Industries INC. | $273.66 | 2021-2025 | Winlevi, Absorica Ld |
| Boston Scientific Corporation | $227.31 | 2025 | Avvigo Guidance System, Stingray |
| Abbott Laboratories | $222.03 | 2022-2025 | Thoratec Heartmate 3 Lvas Implant Kit, Aveir, Optis |
| Organon LLC | $187.10 | 2025 | Vtama |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $153.44 | 2021-2024 | Jublia, Arazlo, Cabtreo |
| Almirall LLC | $150.12 | 2022-2024 | Klisyri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $149.82 | 2022-2025 | Spevigo |
| Vyne Pharmaceuticals INC. | $145.04 | 2021 | |
| Biofrontera INC. | $140.48 | 2022 | |
| Abiomed | $101.28 | 2025 | |
| Allergan, INC. | $97.33 | 2019 | |
| Verrica Pharmaceuticals INC. | $71.25 | 2023-2025 | Ycanth |
| Sanofi-Aventis U.S. LLC | $45.07 | 2021 | |
| Chiesi USA, INC. | $22.51 | 2025 | Filsuvez |
| Organogenesis INC. | $19.03 | 2023 | Puraply |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Imran Aslam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.